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Abstract 
Review on ADAMTS9, with data on DNA/RNA, 
on the protein encoded and where the gene is 
implicated. 
Identity 
HGNC (Hugo): ADAMTS9 
Location: 3p14.1 
DNA/RNA 
Description 
The human ADAMTS9 gene is composed of 40 
exons spanning a genomic region of about 172 kbp. 
The open reading frame of the coding region is 
5808 bp. 
Pseudogene 
No pseudogene reported. 
Protein 
Description 
ADAMTS9 is composed of a signal peptide, a 
propeptide, a metalloproteinase domain, a 
disintegrin-like domain, thrombospondin type 1-
like repeats, a cystein-rich domain, a spacer 
domain, and a unique C-terminal domain 
(Somerville et al., 2003). A unique C-terminal 
domain was named as GON domain. The GON 
domain functions in the ER for protein transport 
from the ER to the Golgi (Yoshina et al., 2012). N-
linked glycosylation of ADAMTS9 propeptide is  
found to be essential for ADAMTS9 secretion (Koo 
et al., 2007). ADAMTS9 is processed by furin 
extracellularly but not in the secretory pathway 
(Koo et al., 2006).  
Following furin processing, mature ADAMTS9 is 
released from the cell surface (Koo et al., 2007). 
ADAMTS9 is required for early mouse 
development. ADAMTS9 null mice die before 
gastrulation. ADAMTS9+/- mice develop 
anomalous eye such as corneal clouding, corneal 
neovascularisation, and adhesions of the lens and 
iris to the cornea (Koo et al., 2010). 
Expression 
ADAMTS9 is found in adult human ovary, 
pancreas, heart, kidney, lung, placenta, and skeletal 
muscle. ADAMTS9 is found in fetal brain, heart, 
kidney, lung, liver, skeletal muscle, spleen and 
thymus. According to northern blot analysis, the 
highest mRNA levels are found in heart, placenta, 
and skeletal muscle (Clark et al., 2000; Somerville 
et al., 2003).  
ADAMTS9 is expressed in microvascular 
endothelial cells (Koo et al., 2010). 
Following stimulation with TNFalpha, ADAMTS9 
mRNA expression was enhanced in a human retinal 
pigment epithelial cell line (ARPE-19) (Bevitt et 
al., 2003). In a human chondrosarcoma cell line 
(OUMS-27) and human chondrocytes, exposure to 
IL-1 beta or TNF alpha upregulate ADAMTS9 
mRNA expression (Demircan et al., 2005). 
Induction of ADAMTS9 mRNA by IL-1beta was 
reported to occur via NFATc binding to the 
ADAMTS9 promoter in the OUMS-27 and in 
human chondrocyte (Yaykasli et al., 2009). 
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Diagram of the human ADAMTS9 protein. 
 
In the human lung carcinoma epithelial cell line 
(A549), exposure to TGF- beta or IL-13 or Epstein-
Barr virus infection led to enhanced ADAMTS9 
mRNA expression. IL-4 exposure had no effect on 
the expression of ADAMTS9 in A549 (Keating et 
al., 2006). 
Localisation 
ADAMTS9 is present at the plasma membrane and 
the endoplasmic reticulum (Somerville et al., 2003; 
Yoshina et al., 2012). 
Function 
ADAMTS9 cleaves aggrecan and versican 
(Somerville et al., 2003). ADAMTS9 is involved in 
cell migration and inhibition of angiogenesis (Koo 
et al., 2010). 
ADAMTS9 is implicated in the transport from the 
endoplasmic reticulum to the Golgi. This function 
is GON-domain dependent but protease activity 
independent (Yoshina et al., 2012). 
Homology 
ADAMTS9 and ADAMTS20 have the identical 
domain organization and exon structure and a 
similar primaly sequence. The unique C-terminal 
domain, GON domain, is highly similar in 
ADAMTS9 and ADAMTS20 (Somerville et al., 
2003). 
Mutations 
Note 
A downregulation of ADAMTS9 has been observed 
in some carcinoma that is induced by aberrant 
methylation of the gene.  
The major C-risk allele of rs4607103 near 
ADAMTS9, conferring increased risk of type 2 
diabetes. 
Implicated in 
Esophageal squamous cell 
carcinoma 
Note 
Complete loss or downregulation of ADAMTS9 
gene expression was found in 15 out of 16 
esophageal carcinoma cell lines. Promoter 
hypermethylation was involved in gene 
downregulation. Downregulation of ADAMTS9 
was also found in primary esophageal tumor tissues 
from Hong Kong and from the high-risk region of 
Henan (Lo et al., 2007). Downregulation of 
ADAMTS9 expression led to tumorigenesis. 
Overexpression of ADAMTS9 induced suppression 
of tumor formation and angiogenesis in esophageal 
carcinoma cell line (Lo et al., 2010). 
Nasopharyngeal carcinoma 
Note 
ADAMTS9 was downregulated in nasopharyngeal 
carcinoma cell lines. The mechanism of 
ADAMTS9 gene inactivation was attributed to 
promoter hypermethylation (Lung et al., 2008). 
Downregulation of ADAMTS9 expression led to 
tumorigenesis. Overexpression of ADAMTS9 
induced suppression of tumor formation and 
angiogenesis in nasopharyngeal carcinoma cell line 
(Lo et al., 2010). 
Colorectal cancer 
Note 
The frequency of ADAMTS9 promoter methylation 
in primary colorectal cancers was significantly 
higher than in normal tissues (Zhang et al., 2010). 
Gastric cancer 
Note 
The frequency of ADAMTS9 promoter methylation 
in primary gastric cancers was significantly higher 
than in normal tissues (Zhang et al., 2010; Du et al., 
2013). ADAMTS9 contributes to the suppression of 
tumorigenesis by decreasing cell proliferation, 
inducing cell apoptosis and inhibiting angiogenesis 
through regulating AKT/mTOR signaling pathway 
(Du et al., 2013). 
Pancreatic cancer 
Note 
The frequency of ADAMTS9 promoter methylation 
in primary pancreatic cancers was significantly 
higher than in normal tissues (Zhang et al., 2010). 
Type II diabetes 
Note 
Genome-wide assosiation studies (GWAS) linked a 
marker near the ADAMTS9 locus to type II 
diabetes (Zeggini et al., 2008). The major C allele 
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of rs4607103, located upstream of ADAMTS9, was 
established as a diabetes risk variant in GWAS. 
rs4607103 is associated with a decrease in insulin 
sensitivity of peripheral tissues (Boesgaard et al., 
2009; Trombetta et al., 2013). 
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